November 2020 - Online Technical Meeting
Meeting objectives:
- Update on Covid-19 pandemic: What’s the new normal?
- Discuss the impact of Covid-19 on WHO cervical elimination goals
- Impact of Covid 19 on Vaccination
- Discuss current situation of vaccination programs across different regions in the world.
- Discuss the impact of Covid-19 on school-based vaccination programs and the strategies to restart the programs.
- Vaccine implementation in LMICS and coverage in HICs.
- Impact of Covid-19 on vaccine clinical trials; country examples with ongoing trials, challenges, and strategies to proceed forward.
- Discuss how the vaccine supply shortage situation will evolve due to the pandemic. - Impact of Covid-19 on HPV Screening and Treatment
- Discuss current situation of screening and treatment programs across different regions in the world.
- Identify successful programs such as ROSE in Malaysia to discuss how Covid has impacted these programs their adapted strategies and what is the way forward.
- Discuss self-sampling as an alternate strategy.
- Discuss strategies to restart screening and treatment in HICs and LMICS.
- Discuss the supply shortage of HPV assays.
- HPV assays validation in Covid-19 times; current prospect and challenges.
- Impact of Covid-19 on HPV screening and treatment Clinical trials; country examples with ongoing trials, challenges, and strategies to proceed forward.
- Discuss modelling strategies to support decision making: What are the information needs for developing robust and accurate models of pandemic impacts.
- Reviewing cervical cancer control disruptions in various countries and assess the impact of Covid-19 on vaccination, screening and treatment.
- Using modelling expertise to determine the intermediate and long term impact of disruptions
- Using modelling to inform decision-making for optimizing mitigation and recovery strategies.
- Turning the impact of COVID-19 into a positive pathway for innovation
- Discuss how Covid-19 can be used as an opportunity to bring more robust techniques to deal with screening and vaccination challenges i.e. mobile clinics, self-sampling, mobile apps, more innovative approaches.
Background document
Thursday, 12 November 2020
SESSION 1: OPENING AND OBJECTIVES
Chairs: Alex Vorsters & Karen Canfell
- Introduction & Welcome
Alex Vorsters (University of Antwerp)
Karen Canfell (Cancer Council NSW)
(Pdf, Video)
- Update on Covid-19 pandemic: what’s the new normal?
Pierre Van Damme (University of Antwerp)
(Pdf, Video)
SESSION 2 (PART 1): IMPACT OF COVID-19 ON HPV VACCINATION
Chairs: Pierre Van Damme & Suzanne Garland
- Guidance for HPV vaccination during Covid-19 pandemic
Paul Bloem (WHO)
(Pdf, Video) - Current situation of HPV vaccination programs across different regions in the world
- Current Situation of HPV Vaccination Programs in the Americas
Lucia de Oliveira (Pan American Health Organization (PAHO)
(Pdf, Video)
- Current Situation of HPV Vaccination Programs in Brazil
Victor Gomes Porto (Ministry of Health Brazil)
(Pdf, Video)
- 10 years of experience in the delivery of HPV vaccine and COVID-19 Impact on vaccination coverage Rwanda
Hassan Sibomana (Rwanda Biomedical Centre)
(Pdf, Video)
- HPV vaccination programme: Current Situation in England
Alejandra Castanon (King’s College London)
(Pdf , Video)
- Current Situation of HPV Vaccination Programs in Japan
Sharon Hanley (Hokkaido University)
(Pdf, Video)
- Current situation of HPV vaccination programs across EU countries
Hélène De Pauw (Sciensano, Belgium)
- Questions & discussions
SESSION 2 (PART 2): IMPACT OF COVID-19 ON HPV VACCINATION
Chairs: Margaret Stanley & Kate Cuschieri
- Interruption of vaccination programs, and strategies to close the immunity gap
UNICEF – Oya Zeren Afsar
(Pdf, Video)
- Lessons learnt from the Ebola outbreak country response, interruption and restarting of vaccination programs - The example of Liberia
Ado Bwaka (WHO)
(Pdf, Video)
- Questions & discussions
- Impact of Covid-19 on single-dose HPV vaccination trials; interruption, current situation and way forward
Aimee Kreimer (National Cancer Institute - NCI) - Questions & discussions
SESSION 3: IMPACT OF COVID-19 ON HPV SCREENING AND TREATMENT
Chairs: Mario Poljak & Xavier Bosch
- Current situation of screening programs across different regions in the world
Laia Bruni (Catalan Institute of Oncology) - Interruption in the screening programme
- ROSE; Adapted Strategy and Moving forward in the Era of Covid-19
Yin Ling Woo (University of Malaya)
(Pdf, Video)
- HPV screening programme: Current Situation in England
Alejandra Castanon (King’s College London)
(Pdf, Video)
- Interruption in the Cervical Screening Programme- COVID-19 and Japan
Sharon Hanley (Hokkaido University)
(Pdf)
- Perspectives Against COVID-19 Pandemic: Impact on Guidelines
Murat Gültekin (European Society of Gynaecological Oncology)
(Pdf , Video)
- Questions & discussions
PANEL DISCUSSION
Chairs: Anna Giuliano & Eduardo Franco
- HPV Vaccine supply landscape; current scenario and future perspective
Tania Cernuschi (WHO)
(Pdf)
- Environmental Scan: Current Status of new HPV vaccine
Peter Dull (Gates Foundation)
(Pdf, Video) - Breakout session
HPV assays shortage and HPV vaccine supply constraints; is 2030 elimination target possible? - Plenary feedback
Friday, 13 November 2020
SESSION 4: MODELLING STRATEGIES TO SUPPORT DECISION MAKING AND MAKE BETTER HEALTH INTERVENTIONS
Chairs: Freddie Bray and Karen Canfell
- Overview of the Covid and Cancer Global Modelling Consortium (CCGMC) efforts in relation to cervical cancer
Karen Canfell (Cancer Council NSW)
(Pdf, Video)
- Current challenges in collating and using cancer registry data to inform recovery planning for cervical cancer control
Freddie Bray (IARC)
(Video)
- LMIC Focus: Modelled near term impact of delays in elimination on cervical cancer cases averted and lives saved before 2030
Kate Simms (Cancer Council NSW)
(Pdf, Video)
- Modelled impact of Covid related disruptions on cervical screening in the USA
Emily Burger (Harvard T.H. Chan School of Public Health)
(Pdf) - Modelled impact of Covid related disruptions on cervical screening in the first CCGMC multi-country analysis
Megan Smith (Cancer Council NSW)
- Panel Discussion (all speakers): Discussion Video
- What data do we need to inform the modelling of Covid impacts and optimal recovery strategies?
- What recovery strategies should we prioritize for evaluation?
SESSION 5: TURNING IMPACT OF COVID-19 INTO PATHWAY FOR INNOVATION
Chairs: Paolo Bonanni & Nubia Muñoz
- Approaches on how to generate a covid free space and re/evaluate the priorities
Silvia de Sanjosé (National Cancer Institute and PATH)
- Is self-sampling a solution to overcome COVID-19 related decreases in screening coverage
Marc Arbyn (Sciensano)
(Pdf, Video)
- GAVI INNOVATION CATALOGUE v1.0: Maintaining, restoring & strengthening immunization
Charlie Whetham (GAVI)
(Pdf, Video)
- Questions & Discussion
BREAKOUT SESSION
- Breakout session
- Lessons learned from this meeting
- Steps needed for the future
- How can we make a difference?
- Plenary feedback
SESSION 6: CONCLUSION
Chair: Alex Vorsters
- Conclusion and concluding remarks
Marc Baay (P95)
(Pdf)
Alex Vorsters (University of Antwerp)